Immune response to racotumomab in a child with relapsed neuroblastoma
Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-gly...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2012-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00195/full |
| _version_ | 1818583270923698176 |
|---|---|
| author | CLAUDIA VANESA SAMPOR Marcelo David Guthmann Alejandra eScursoni Walter eCacciavillano Ana eTorbidoni Laura eGalluzzo Sandra eCamarero Jessica eLopez Maria Teresa eGarcia de Davila Leonardo eFainboim Guillermo eChantada Guillermo eChantada |
| author_facet | CLAUDIA VANESA SAMPOR Marcelo David Guthmann Alejandra eScursoni Walter eCacciavillano Ana eTorbidoni Laura eGalluzzo Sandra eCamarero Jessica eLopez Maria Teresa eGarcia de Davila Leonardo eFainboim Guillermo eChantada Guillermo eChantada |
| author_sort | CLAUDIA VANESA SAMPOR |
| collection | DOAJ |
| description | Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside. |
| first_indexed | 2024-12-16T08:02:37Z |
| format | Article |
| id | doaj.art-170d1e011b824347ad02e9dcd04b5dc5 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-16T08:02:37Z |
| publishDate | 2012-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-170d1e011b824347ad02e9dcd04b5dc52022-12-21T22:38:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2012-12-01210.3389/fonc.2012.0019535856Immune response to racotumomab in a child with relapsed neuroblastomaCLAUDIA VANESA SAMPOR0Marcelo David Guthmann1Alejandra eScursoni2Walter eCacciavillano3Ana eTorbidoni4Laura eGalluzzo5Sandra eCamarero6Jessica eLopez7Maria Teresa eGarcia de Davila8Leonardo eFainboim9Guillermo eChantada10Guillermo eChantada11Pediatric Hospital Dr. J.P. GARRAHANELEA LaboratoryPediatric Hospital Prof. Dr J.P. GARRAHANPediatric Hospital Dr. J.P. GARRAHANPediatric Hospital Prof. Dr J.P. GARRAHANPediatric Hospital Prof. Dr J.P. GARRAHANPediatric Hospital Prof. Dr J.P. GARRAHANPediatric Hospital Prof. Dr J.P. GARRAHANPediatric Hospital Prof. Dr J.P. GARRAHANJose de San Martin Clinics HospitalPediatric Hospital Dr. J.P. GARRAHANPediatric Hospital Dr. J.P. GARRAHANImmunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00195/fullImmunotherapyNeuroblastomamonoclonal antibodiesgangliosideracotumomab. |
| spellingShingle | CLAUDIA VANESA SAMPOR Marcelo David Guthmann Alejandra eScursoni Walter eCacciavillano Ana eTorbidoni Laura eGalluzzo Sandra eCamarero Jessica eLopez Maria Teresa eGarcia de Davila Leonardo eFainboim Guillermo eChantada Guillermo eChantada Immune response to racotumomab in a child with relapsed neuroblastoma Frontiers in Oncology Immunotherapy Neuroblastoma monoclonal antibodies ganglioside racotumomab. |
| title | Immune response to racotumomab in a child with relapsed neuroblastoma |
| title_full | Immune response to racotumomab in a child with relapsed neuroblastoma |
| title_fullStr | Immune response to racotumomab in a child with relapsed neuroblastoma |
| title_full_unstemmed | Immune response to racotumomab in a child with relapsed neuroblastoma |
| title_short | Immune response to racotumomab in a child with relapsed neuroblastoma |
| title_sort | immune response to racotumomab in a child with relapsed neuroblastoma |
| topic | Immunotherapy Neuroblastoma monoclonal antibodies ganglioside racotumomab. |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00195/full |
| work_keys_str_mv | AT claudiavanesasampor immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT marcelodavidguthmann immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT alejandraescursoni immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT walterecacciavillano immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT anaetorbidoni immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT lauraegalluzzo immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT sandraecamarero immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT jessicaelopez immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT mariateresaegarciadedavila immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT leonardoefainboim immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT guillermoechantada immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma AT guillermoechantada immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma |